Navigation Links
Pure MHC and Catalent Sign RL21 Anti-Cancer Development Deal
Date:11/21/2013

Somerset, NJ, and Austin, TX (PRWEB) November 21, 2013

Pure MHC, LLC, a provider of MHC-based diagnostics and therapeutics, and Catalent Pharma Solutions, the global leader in drug development solutions and advanced delivery technologies for pharmaceutical, biologic and consumer health products, today announced the signing of a product development agreement. Under the terms of the agreement, Catalent will develop a humanized version of Pure MHC’s proprietary RL21A antibody and engineer a cell line to express the antibody using Catalent’s GPEx® technology. Catalent will subsequently produce purified monoclonal antibodies to support Pure MHC’s preclinical development in preparation for clinical trials with humanized RL21A for the treatment of cancer. GPEx technology is used to generate mammalian cells with high yields and stability, helping to speed drugs to clinic.

“We are confident that our partnership with Catalent will result in the development of the enhanced antibodies necessary to help get RL21A into the clinic more quickly,” said Thomas Harlan, CEO of Pure MHC, “Our ultimate goal for this technology is to one day provide cancer patients with a treatment option that is safer and more effective than those available today.”

“We are delighted to again demonstrate how GPEx technology, together with Catalent’s development and manufacturing expertise, can support development of novel therapies and enable companies such as Pure MHC to validate their unique target screening methodology,” said Jonathan Arnold, VP, General Manager of Catalent’s Advanced Delivery Technologies business.

Pure MHC has developed a suite of MHC/ligand targets that recognize cancerous cells in addition to producing monoclonal antibodies for these distinct MHC/ligand cancer targets. Antibodies such as RL21A distinguish primary cancers from healthy tissue and, in animal models, have been shown to arrest tumor development.

<
'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related medicine news :

1. Catalent Creates New Advanced Delivery Technologies Business Unit
2. Catalent’s Clinical Trial Supply Facility in Shanghai, China Opens for Business
3. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
4. 1960s-era anti-cancer drug points to treatments for Lou Gehrigs disease
5. Specialized MRI scans assess value of anti-cancer chemotherapy long before tumors shown to shrink
6. First trial in humans of minicells: A completely new way of delivering anti-cancer drugs
7. Development of the first way to make large amounts of promising anti-cancer substance
8. Progress after recent breakthrough which opened new chapter in anti-cancer cell therapies
9. Overcoming resistance to anti-cancer drugs by targeting cell powerhouses
10. Anti-cancer drug viewed as possible Alzheimers treatment doesnt work in UF study
11. New understanding of why anti-cancer therapy stops working at a specific stage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based facial plastic ... med-spa with the addition of new Silk Peel skin ... and services. , “Silk Peel is a procedure that ... “As a result it can address issues like acne ... or blemishes.” , Similar to microdermabrasion, Silk Peel ...
(Date:12/24/2014)... Mike Billings , PT, MS, CEEAA, President ... PT, MBA, GCS, Director of Professional Development to discuss ... of the Improving Medicare Post-Acute Care Transformation Act ... the Infinicast, the two leaders discuss how the IMPACT ... to standardize post-acute assessment data for quality, payment, and ...
(Date:12/24/2014)... (HealthDay News) -- A new, injectable weight-loss drug has ... The agency on Tuesday approved Saxenda (liraglutide) for ... overweight and have at least one weight-related health condition, ... high cholesterol. Patients taking the drug, made by ... exercise regularly, the FDA noted. "Obesity is a ...
(Date:12/24/2014)... Steven Reinberg HealthDay ... New guidelines from the American Diabetes Association (ADA) call for ... with diabetes to help prevent heart disease. These new ... of Cardiology and American Heart Association, which also recommend giving ... heart disease, including people with diabetes. "We agree that ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 24, 2014 ... COC Industry is a professional and in-depth research ... the report introduces COC basic information, including its ... policy analysis, news analysis, etc. This report also ... structure etc. Production is separated by regions, technology ...
Breaking Medicine News(10 mins):Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3
... ATLANTA, Sept. 23 The Hospital of Central Connecticut (THOCC), ... IM Practice Manager to automate, organize and increase quality of ... physicians at THOCC will be using IM,s handheld and Internet-based solution, ... users, making it the most widely used electronic charge capture system ...
... , SALT LAKE CITY, Sept. 23 Dynatronics Corporation ... quarter and year ended June 30, 2009 during the morning of Friday, ... its third consecutive quarter of profitability. , , Dynatronics ... p.m. ET to discuss its results for the quarter and year periods. ...
... , , ROCHESTER, N.Y., Sept. 23 ... R. Kerry Clark and Robert J. Palmisano have joined its board ... outstanding business leaders with broad and relevant experience," said Gerald M. ... these help us become better positioned for long-term growth. We welcome ...
... Foundation recently received a $1 million planned-gift donation ... radiology fellows to pursue this medical profession. SIR ... of interventional radiology by specializing in developing investigators ... research. "This enormously generous gift supports the ...
... Washington DC (September23, 2009) SAGE is partnering with the ... in 2010. A peer-reviewed quarterly journal, Cartilage will ... many types of researchers and clinicians involved in cartilage biology ... Cartilage is edited by Roy D. Altman, M.D., ...
... H1N1 influenza could slow growth in key industries and ... of 2009, says a health economist in the University of ... travel are vitally important sectors in the economy of many ... severity of the spread of the virus, consumers and businesses ...
Cached Medicine News:Health News:The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 2Health News:The Hospital of Central Connecticut Selects Ingenious Med for Inpatient Practice Management 3Health News:R. Kerry Clark and Robert J. Palmisano Join Bausch & Lomb Board of Directors 2Health News:Society of Interventional Radiology Foundation receives $1 million legacy gift 2Health News:Swine flu could wreak more havoc on US economy, says UAB economist 2
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
(Date:12/24/2014)... Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) released unaudited preliminary financial results ... Fiscal Year 2015 Ended September 30, ... million compared with $14.7 million in 1Q14 with ...
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today that on December 24, 2014 ... The Company raised approximately $2.3 million ... to use the net proceeds from the offering ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... Inc. (Nasdaq: BNVI ) announced today that it will ... 2009 ended September 30, 2009 on Thursday, November 5, 2009. ... to review the financial results on Thursday, November 5, 2009 ... call by dialing (800) 860-2442 or (412) 858-4600, or can ...
... October 29 Amsterdam Molecular,Therapeutics (AMT) and Progenika Biopharma ... and commercialization agreement for,LPLchip(TM), a diagnostic tool to rapidly ... AMT has developed Glybera(R) as,a gene therapy for patients ... June of this year AMT announced new clinical data ...
Cached Medicine Technology:AMT Starts Development LPLChip(TM) With Progenika 2AMT Starts Development LPLChip(TM) With Progenika 3
30 Degree Angle Shaft with 1.0mm 90 Degree Angle Tip; in stainless steel....
0.5mm "K" hook. Rounded knurled handle; shaft angled 11mm from tip; overall length 120mm, in Titanium....
Lightly Curved-Blunt Tips Rounded Blades; 1mm Eye in Blades; 27mm from mid screw to tip. Matte finish; Stainless Steel, overall length 120mm...
... Catheter is indicated for balloon ... of a coronary artery or ... purpose of improving myocardial perfusion. ... also designed to provide distal ...
Medicine Products: